| Autor: |
Lai, Tony, Yeo, Chin-Yen, Rockliff, Bradley, Stokes, Michael, Kim, Hannah Yejin, Marais, Ben J, McLachlan, Andrew J, Alffenaar, Jan-Willem C |
| Předmět: |
|
| Zdroj: |
Journal of Antimicrobial Chemotherapy (JAC); Apr2024, Vol. 79 Issue 4, p703-711, 9p |
| Abstrakt: |
Introduction Therapeutic drug monitoring (TDM) is a tool that supports personalized dosing, but its role for liposomal amphotericin B (L-amb) is unclear. This systematic review assessed the evidence for L-amb TDM in children. Objectives To evaluate the concentration–efficacy relationship, concentration–toxicity relationship and pharmacokinetic/pharmacodynamic (PK/PD) variability of L-amb in children. Methods We systematically reviewed PubMed and Embase databases following PRISMA guidelines. Eligible studies included L-amb PK/PD studies in children aged 0–18 years. Review articles, case series of max/MIC) of 25–50 for optimal efficacy and an AUC24 of >600 mg·h/L for nephrotoxicity. L-amb doses of 2.5–10 mg/kg/day were reported to achieve C max/MIC > 25 using an MIC of 1 mg/L. Conclusions While significant PK variability was observed in children, evidence to support routine L-amb TDM was limited. Further studies on efficacy and toxicity benefits are required before routine TDM of L-amb can be recommended. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
